Michigan Medicine Researcher Reports Research in Dermatology (Limited health insurance coverage of injectable neurotoxins and fillers for gender affirmation: a cross-sectional study of Affordable Care Act silver and Medicaid plans): Health and Medicine – Dermatology

2024 FEB 16 (NewsRx) -- By a News Reporter-Staff News Editor at Health Policy and Law Daily -- Researchers detail new data in dermatology. According to news reporting out of Ann Arbor, Michigan, by NewsRx editors, research stated, “Injectable neurotoxins and fillers are potential options for facial gender affirmation for transgender/nonbinary patients. However, the largest barrier to access is cost/insurance coverage.”

The news reporters obtained a quote from the research from Michigan Medicine: “The purpose of this article is to assess the extent to which Affordable Care Act (ACA) silver plans and Medicaid policies cover gender-affirming injectable neurotoxin and filler procedures. A cross-sectional study of all ACA silver plans and Medicaid policies was performed from June 22 to August 15, 2021. Plan-specific certificates of coverage, clinical policies of insurance providers, and Medicaid documents were evaluated. A total of 915 plans were reviewed (864 ACA silver plans and all 51 Medicaid policies). None potentially covered neurotoxins. Only 72 (71 ACA and 1 Medicaid) potentially covered fillers, specifically collagen injections and lipofilling. Coverage required demonstration of medical necessity or significant variation of physical appearance from the patient’s experienced gender. However, of the 71 ACA plans, 69 outlined cosmetic exclusions, possibly nullifying this coverage. Limitations: Data were sourced from publicly available online information in 2021. Additionally, we were unable to confirm explicit coverage of these procedures with insurance companies.”

According to the news editors, the research concluded: “The majority of ACA silver and Medicaid plans did not cover gender-affirming neurotoxin or filler procedures, limiting access to this gender-affirming care.”

For more information on this research see: Limited health insurance coverage of injectable neurotoxins and fillers for gender affirmation: a cross-sectional study of Affordable Care Act silver and Medicaid plans. International Journal of Women’s Dermatology, 2024,10(1). (International Journal of Women’s Dermatology - http://www.journals.elsevier.com/international-journal-of-womens-dermatology/). The publisher for International Journal of Women’s Dermatology is Ovid Technologies (Wolters Kluwer Health).

A free version of this journal article is available at https://doi.org/10.1097/jw9.0000000000000126.

Our news journalists report that more information may be obtained by contacting Karin Roszell, Department of Dermatology, Michigan Medicine, Ann Arbor, Michigan, United States. Additional authors for this research include Daniel Shumer, Jeffrey Orringer, Frank Wang.

(Our reports deliver fact-based news of research and discoveries from around the world.)